

Table of Contents

1.	Chapter 1 1 – General Principles	1
1.1	Introduction.....	1
1.2	Basic Concepts.....	1
1.3	Why Model the Data?.....	2
1.4	The Art of Successful Modeling.....	4
1.5	How to Use This Book	7
2.	CHAPTER 2 – Pharmacokinetic Concepts	13
2.1	Background	13
2.2	One-Compartment Models.....	14
2.2.1	Intravenous bolus administration	14
2.2.2	Constant rate infusion	22
2.2.3	Integration of clearance and volume	25
2.2.4	Extravascular administration	28
2.2.5	Estimation of absorption parameters from first-order input	32
2.2.6	Estimation of absorption parameters from zero-order input	38
2.2.7	What lies behind the apparent absorption rate constant?	40
2.2.8	Estimation of bioavailability	41
2.2.9	How does input to the plasma compartment vary?	43
2.2.10	Multiple dosing.....	43
2.2.11	Absorption from multiples sites	46
2.2.12	Conclusions for extravascular dosing	47
2.3	Plasma and Urine Data.....	48
2.3.1	Basic renal physiology	48
2.3.2	Derivation of equations	48
2.3.3	Analysis of urinary excretion data	50
2.3.4	Estimation of bioavailability from urinary data	56
2.4	Multi-Compartment Models.....	57
2.4.1	Catenary and mammillary models	57
2.4.2	Intravenous bolus administration	59
2.4.3	Reparameterization of the two-compartment model.....	66
2.4.4	Constant rate infusion	72
2.4.5	Extravascular administration.....	74
2.4.6	Plasma and urine data	76
2.5	Clearance Concepts	77
2.5.1	Derivation of clearance.....	77
2.5.2	Extraction.....	79
2.5.3	Impact of route of administration	83
2.5.4	<i>In vitro/in vivo</i> comparisons of clearance	85
2.5.5	Hepatic clearance models.....	90
2.5.6	Additional readings.....	94
2.6	Turnover	94
2.6.1	Background	94

2.6.2	Introduction to turnover of proteins, peptides and antibodies	97
2.6.3	Turnover of immunoglobulins.....	100
2.6.4	Turnover of hormones - Estradiol	102
2.6.5	Comparison of models.....	104
2.6.6	Turnover of body temperature	106
2.6.7	Feedback.....	110
2.7	Nonlinear Systems – Capacity, Time, Flow and Binding.....	112
2.7.1	What causes nonlinearity and how is it assessed?	112
2.7.2	Nonlinear kinetics – Capacity	114
2.7.2.1	Bolus input - Capacity limited elimination	117
2.7.2.2	Constant rate input - Capacity limited elimination	118
2.7.2.3	First order input - Capacity limited elimination	118
2.7.2.4	Conclusions for capacity limited elimination.....	118
2.7.3	Nonlinear kinetics - Time.....	119
2.7.3.1	Background	119
2.7.3.2	Turnover of induction.....	120
2.7.3.3	Heteroinduction – Pentobarbital induction of nortriptyline	123
2.7.3.4	Autoinduction.....	126
2.7.4	Nonlinear kinetics - Flow	129
2.7.5	Nonlinear kinetics - Binding.....	129
2.7.6	Nonlinear drug and metabolite models	135
2.7.7	Ethanol combines capacity, time and flow dependencies	139
2.8	Non-Compartmental Analysis.....	141
2.8.1	Non-compartmental versus regression analysis.....	141
2.8.2	Computational methods – Linear trapezoidal rule	142
2.8.3	Computational methods – Log-linear trapezoidal rule	144
2.8.4	Strategies for estimation of λ_z	146
2.8.5	Pertinent pharmacokinetic estimates.....	148
2.8.6	Issues related to steady state.....	152
2.8.7	Metabolite kinetics	155
2.8.8	When half-life is short relative to input time	157
2.9	How to Assess Exposure	158
2.9.1	What do we mean by exposure?.....	158
2.9.2	The case(s) for abandoning dose	158
2.9.3	Exposure based on total concentrations	163
2.9.4	Exposure based on unbound concentrations	167
2.9.5	Conclusions about exposure.....	169
2.10	Inter-Species Scaling.....	170
2.10.1	When and why do we extrapolate data across species?	170
2.10.2	What is allometry?.....	172
2.10.3	Allometric equations.....	173
2.10.4	Time scales differ between different species.....	181
2.10.5	Estimation of parameters	183
2.10.6	The elementary Dedrick plot.....	184
2.10.7	The complex Dedrick plot	186
2.10.8	Integration of concepts	189

2.10.9	Physiological variables of 11 animal species and man	191
2.10.10	Allometric scaling of turnover parameters.....	194
2.10.11	General conclusions about exposure and scaling.....	196
2.11	Additional Reading	198
3.	CHAPTER 3 – Pharmacodynamic Concepts	199
3.1	Background	199
3.2	Definitions	200
3.3	Law of Mass Action.....	202
3.4	Receptor Binding Models	206
3.4.1	Saturation studies	206
3.4.2	Displacement studies.....	207
3.5	Pharmacodynamic Models.....	210
3.5.1	Background.....	210
3.5.2	Linear effect-concentration model	210
3.5.3	Log-linear effect-concentration model	211
3.5.4	Ordinary E_{max} model	213
3.5.5	Sigmoid E_{max} model	216
3.5.6	Composite E_{max} model used to capture <i>mixture dynamics</i>	221
3.5.7	Multiple binding site model.....	224
3.6	Interaction Models.....	224
3.6.1	Competitive antagonism.....	224
3.6.2	Noncompetitive antagonism.....	225
3.6.3	General empirical dynamic model for two drugs.....	226
3.6.4	Enantiomer interaction models	227
3.6.5	Additional sigmoidal models.....	228
3.6.6	Kinetics of pharmacological responses.....	229
3.6.7	Area under the response-time curve.....	233
3.7	Turnover Models – Reversible Drug Effects.....	235
3.7.1	Background	235
3.7.2	Turnover model taxonomy	236
3.7.3	Model characteristics	246
3.7.4	Initial parameter estimates.....	247
3.7.5	Model behavior	252
3.7.6	Model extensions.....	254
3.8	Turnover Models – Irreversible Drug Effects	256
3.8.1	Simple irreversible action – Cell killing.....	257
3.8.2	Cell growth coupled with cell killing	258
3.8.3	Minimum inhibitory concentration.....	260
3.9	Effect Compartment (Link) Models	261
3.9.1	Background	261
3.9.2	One-compartment models	264
3.9.3	Two-compartment models	266
3.9.4	Integration of time into the Hill equation.....	268
3.9.5	Alternative parameterizations	268
3.9.6	Some literature examples and simulations.....	269

3.9.7	Problems and pitfalls.....	271
3.10	Dose-Response-Time Models.....	272
3.10.1	Background.....	272
3.10.2	Miotic data.....	273
3.10.3	Locomotor activity.....	275
3.10.4	Antinociception.....	278
3.10.5	Body temperature.....	280
3.10.6	Turnover of antipsychotic effects.....	282
3.10.7	Conclusions about dose-response-time data modeling.....	283
3.11	Tolerance and Rebound Models.....	284
3.11.1	Background.....	284
3.11.2	Systems analysis.....	288
3.11.3	Time dependent attenuation of parameters.....	288
3.11.4	Antagonistic metabolite model.....	291
3.11.5	Tolerance compartment model.....	292
3.11.6	Counteracting mechanisms.....	293
3.11.7	Feedback and rebound.....	294
3.11.8	Simple negative feedback on turnover rate.....	296
3.11.9	Negative feedback via a moderator.....	297
3.11.10	Negative feedback via a moderator and level of response.....	301
3.11.11	Simulation of negative feedback via a moderator.....	302
3.11.12	Pool model – Unidirectional flow.....	304
3.11.13	Pool model – Bidirectional flow.....	307
3.11.14	Comparisons with other models.....	309
3.11.15	Modeling of EEG-time data.....	312
3.11.16	Some thoughts about tolerance and dependence models.....	316
3.12	Baseline models.....	317
3.12.1	Constant <i>versus</i> variable baseline models.....	317
3.12.2	Oscillating turnover rates.....	320
3.13	Transduction Models.....	323
3.14	Synergistic Effects Modeled by Turnover Functions.....	325
3.15	Synergistic Effects Modeled by Hyperbolic Functions.....	327
3.16	Logistic Response Models.....	329
3.17	Additional Reading.....	332
4.	CHAPTER 4 – Modeling Strategies.....	333
4.1	Background.....	333
4.2	Plot and Explore Data.....	334
4.2.1	Understand your experimental data better.....	334
4.2.2	Pooling of data from multiple subjects.....	335
4.2.3	Transformation for exploration.....	337
4.2.4	Transformation for fitting.....	339
4.2.5	Normalizing data.....	341
4.3	How Complicated a Model?.....	342
4.3.1	How many parameters?.....	342
4.3.2	How do we specify the model?.....	343

4.3.3	Combining several sources of data for analysis	347
4.3.4	Parameter identifiability	348
4.3.5	Ability to estimate parameters	350
4.4	Obtaining Initial Estimates.....	352
4.4.1	Graphical methods and linear regression.....	353
4.4.1.1	Kinetic data.....	353
4.4.1.2	Dynamic equilibrium data.....	355
4.4.1.3	Dynamic non-steady state data.....	356
4.4.1.4	Dynamic repeated dose data	360
4.4.2	When all else fails.....	363
4.5	Iterations	365
4.7	Assessing the Goodness-of-Fit	368
4.7.1	Analyzing the residuals.....	369
4.7.2	Graphical presentation of residuals.....	371
4.7.3	Pure error <i>versus</i> lack of fit.....	377
4.7.4	Parameter estimates - Accuracy	379
4.7.5	Parameter estimates - Precision.....	380
4.7.6	Correlation between observed and predicted values	381
4.7.7	Correlation between parameters	382
4.7.8	Some comments on the use of <i>WRSS versus -2·Log Likelihood function</i>	386
4.8	Discrimination Between Rival Models	386
4.8.1	F test	387
4.8.1.1	Background	387
4.8.1.2	The ordinary E_{max} <i>versus</i> the sigmoid E_{max} models.....	388
4.8.1.3	The ordinary E_{max} <i>versus</i> the linear response model.....	388
4.8.1.4	The hepatic distributed <i>versus</i> parallel tube model	388
4.8.2	Akaike and Schwarz criteria	389
4.9	Outliers	390
4.10	A Checklist for Assessing Godness-of-Fit	391
5.	CHAPTER 5 – Elements of Experimental Design.....	393
5.1	Background	393
5.2	Tools for Experimental Design	394
5.2.1	Delta Δ function.....	394
5.2.2	Variance inflation factor	396
5.2.3	Partial derivatives	399
5.2.4	Sensitivity analysis.....	404
5.3	Challenges in Experimental Design.....	406
5.3.1	Bolus, infusion and first-order input	406
5.3.2	Concentration- and time-dependent kinetics.....	410
5.3.3	Design of toxicokinetic studies	412
5.3.4	Acute <i>versus</i> chronic dosing	415
5.3.5	Schedule dependence	418
5.3.6	A Strategy for increasing information to model building – individualization of dosing	419
5.3.7	Active metabolites.....	420

6.	CHAPTER 6 – Pattern Recognition	423
6.1	Background	423
6.1	Single and multiple response-time profiles I	424
6.3	Single and multiple response-time profiles II	429
6.4	Single and multiple response-time and concentration-response profiles III	437
6.5	Single and multiple response-time and concentration-response profiles IV	442
6.6	Single and multiple response-time profiles V	447
6.7	Single and multiple concentration-time profiles VI	453
6.8	Single and multiple concentration-time, dose-concentration and parameter-time profiles VII	461
6.9	Conclusions – Pharmacokinetic and Pharmacodynamic Applications	465
	 Pharmacokinetic Applications	 467
PK1	One-compartment intravenous bolus dosing	469
PK2	One-compartment oral dosing	476
PK3	One-compartment 1 st - and 0-order input	483
PK4	One-compartment oral dosing	487
PK5	One-compartment intravenous plasma/urine I	494
PK6	One-compartment intravenous plasma/urine II	500
PK7	Two-compartment intravenous bolus dosing	505
PK8	Two-compartment distribution models	513
PK9	Modeling of fraction absorbed and nonlinear bioavailability across the liver: Simultaneously fitting intravenous and oral data	518
PK10	Simultaneous fitting of iv/po data	525
PK11	Two-compartment repeated oral dosing	528
PK12	Intravenous and oral dosing	532
PK13	Bolus plus constant rate infusion	537
PK14	Multi-compartment model oral dosing	540
PK15	Toxicokinetics	546
PK16	Two-compartment intravenous plasma/urine	549
PK17	Nonlinear kinetics - Capacity I	553
PK18	Capacity II – Ethanol kinetics	556
PK19	Capacity III - Metabolite kinetics	563
PK20	Capacity IV - Nonlinear kinetics	570
PK21	Nonlinear kinetics – Heteroinduction	575
PK22	Nonlinear kinetics - Autoinduction	580
PK23	Nonlinear kinetics - Flow I	586
PK24	Nonlinear kinetics - Flow II	590
PK25	Two-compartment plasma and urine analysis with rate and ARE plots	596
PK26	Modelling of antibody kinetics after i.v. doses to man	599
PK27	Target mediated drug disposition	602
PK28	Allometry – Elementary Dedrick plot	611
PK29	Allometry - Complex Dedrick Plot	615
PK30	Turnover I – Sc dosing of hormone	621
PK31	Turnover II – Intravenous dosing of hormone	624
PK32	Turnover III – Nonlinear disposition	629
PK33	Transdermal input and kinetics	634

PK34	Reversible metabolism	638
PK35	Bayesian model - Digoxin	641
PK36	Time controlled drug delivery	644
PK37	<i>In vitro/in vivo</i> extrapolation I	646
PK38	<i>In vitro/in vivo</i> extrapolation II	650
PK39	Two-compartment data – Experimental design issues	653
PK40	Enterohepatic recirculation	658
PK41	Multiple intravenous infusions - NCA <i>versus</i> regression	661
PK42	Saturable absorption via transporters	665
PK43	Multiple absorption routes	670
PK44	Estimation of inhibitory constant K_i	674
PK45	Reversible metabolism of drug A and its metabolite B	677
PK46	Long infusion and short half-life	686
PK47	Plasma protein binding modeling	690
PK48	One-compartment Michaelis-Menten kinetics – Drug and metabolite in urine	694
PK49	Turnover IV - Factor II data in healthy volunteers	698
PK50	Analysis of multiple subjects concentration- and response-time profiles	704
PK51	Multi-compartment drug/metabolite	711
PK52	Simulated impact of disease on r-hSOD kinetics	716
PK53	Linear antibody kinetics	721

Pharmacodynamic Applications 725

PD1	Receptor binding models	725
PD2	One- and two-site receptor binding	729
PD3	Inhibitory I_{max} model	732
PD4	Turnover model 1 – Intravenous bolus dosing	742
PD5	Turnover model 2 - Intravenous infusions	753
PD6	Turnover model 3 – Turnover <i>versus</i> effect compartment modeling	758
PD7	Turnover model 4 – Iv infusions	764
PD8	Analysis of concentration-glucose response-time data after repeated dosing: Hill <i>versus</i> log-linear models	770
PD9	Turnover model 1 – Repeated dosing I	777
PD10	Comparisons of turnover models 1 and 4 – Intravenous infusions	785
PD11	‘Sigmoidal’ concentration-response models	791
PD12	Modeling inhibition of enzyme activity by means of turnover	797
PD13	Tolerance I – Repeated intravenous infusions	805
PD14	Modeling functional adaptation of EEG data	810
PD15	Oscillating response	819
PD16	Turnover model - Irreversible action	822
PD17	Composite model I - I_{max}	825
PD18	Composite model II - E_{max} / I_{max}	828
PD19	Enantiomer interaction	832
PD20	Effect compartment I – Intravenous bolus	836
PD21	Analysis and comparisons of link-, turnover- and receptor binding models	840
PD22	Effect compartment III – Intravenous infusion	849
PD23	Tolerance development of SSRI-induced 5-HT turnover	854

PD24	Hormone-biomarker interaction	860
PD25	Dose-response-time analysis I	864
PD26	Dose-response-time analysis II	868
PD27	Dose-response-time analysis III	874
PD28	Dose-response-time analysis IV	880
PD29	Synergy via hyperbolic functions	884
PD30	Truncated response data	887
PD31	Consecutive escalating infusions – Safety data	891
PD32	Scaling PD and PK data – Efficacy	895
PD33	Turnover of antipsychotic response	901
PD34	Agonist/antagonist interaction model	907
PD35	Transduction modeling – Assessment of number of transit compartments	910
PD36	Plasma protein binding changes the concentration-response relationship	915
PD37	Multiple binding site model	920
PD38	Turnover model 1 - Repeated dosing II	922
PD39	Turnover model of synergistic effects	927
PD40	Dual action turnover model	932
PD41	Receptor on/off rate model	939
PD42	Pool model of antilipolytic effect	943
PD43	Analysis of a tissue growth/kill model	948
PD44	Exponential concentration-response model of normal and diseased animals	952
PD45	Analysis of brain occupancy data	956
PD46	Exercise on mRNA and protein turnover	959
PD47	Analysis of monophasic action potential duration MAPD	968
PD48	Modeling of functional adaptation – NiAc and NEFA	972
PD49	Modeling tolerance and rebound after multiple intravenous infusions	980
PD50	Pharmacodynamics of an LXR agonist	985
PD51	Modeling Acetylcholinesterase response in the brain after multiple intravenous infusions	990
PD52	Dose-response-time data analysis of locomotor activity	997
References		1003
	Pharmacokinetics-pharmacodynamics	1003
	Data analysis	1021
Symbols and their definitions		1023
Index		1031